Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients
CONCLUSION: The roxadustat dose required to maintain target hemoglobin in NDD patients in Japan with anemia of CKD relative to DA dose may not be impacted by low-grade inflammation. Roxadustat may be beneficial for ESA-hyporesponsive NDD CKD patients.PMID:34628408 | DOI:10.1159/000519043 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - October 10, 2021 Category: Urology & Nephrology Authors: Tadao Akizawa Keiko Tanaka-Amino Tetsuro Otsuka Yusuke Yamaguchi Source Type: research
Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients
CONCLUSION: The roxadustat dose required to maintain target hemoglobin in NDD patients in Japan with anemia of CKD relative to DA dose may not be impacted by low-grade inflammation. Roxadustat may be beneficial for ESA-hyporesponsive NDD CKD patients.PMID:34628408 | DOI:10.1159/000519043 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - October 10, 2021 Category: Urology & Nephrology Authors: Tadao Akizawa Keiko Tanaka-Amino Tetsuro Otsuka Yusuke Yamaguchi Source Type: research
Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients
CONCLUSION: The roxadustat dose required to maintain target hemoglobin in NDD patients in Japan with anemia of CKD relative to DA dose may not be impacted by low-grade inflammation. Roxadustat may be beneficial for ESA-hyporesponsive NDD CKD patients.PMID:34628408 | DOI:10.1159/000519043 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - October 10, 2021 Category: Urology & Nephrology Authors: Tadao Akizawa Keiko Tanaka-Amino Tetsuro Otsuka Yusuke Yamaguchi Source Type: research
Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients
CONCLUSION: The roxadustat dose required to maintain target hemoglobin in NDD patients in Japan with anemia of CKD relative to DA dose may not be impacted by low-grade inflammation. Roxadustat may be beneficial for ESA-hyporesponsive NDD CKD patients.PMID:34628408 | DOI:10.1159/000519043 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - October 10, 2021 Category: Urology & Nephrology Authors: Tadao Akizawa Keiko Tanaka-Amino Tetsuro Otsuka Yusuke Yamaguchi Source Type: research
Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients
Conclusion: The roxadustat dose required to maintain target hemoglobin in NDD patients in Japan with anemia of CKD relative to DA dose may not be impacted by low-grade inflammation. Roxadustat may be beneficial for ESA-hyporesponsive NDD CKD patients.Am J Nephrol (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - October 8, 2021 Category: Neurology Source Type: research
Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HF
ConclusionsIn patients with HF and anemia, both higher baseline serum GDF-15 levels and an increase in GDF-15 during follow-up, were associated with worse clinical outcomes. GDF-15 did not identify subgroups of patients who might benefit from correction of anemia but was associated with several indices of anemia and iron status in the HF patients.Graphic abstract (Source: Clinical Research in Cardiology)
Source: Clinical Research in Cardiology - October 5, 2021 Category: Cardiology Source Type: research
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial
CONCLUSION: In the MIYABI ND-C study, molidustat appeared to be an efficacious and generally well-tolerated alternative to darbepoetin for the treatment of renal anemia in Japanese patients who were not undergoing dialysis and were not receiving ESA treatment.PMID:34569489 | DOI:10.1159/000518071 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
CONCLUSION: Molidustat was noninferior to darbepoetin and maintained Hb levels in the prespecified target range in patients with renal anemia not undergoing dialysis and previously treated with ESA. Molidustat was well tolerated, and no new safety signal was observed.PMID:34569482 | DOI:10.1159/000518072 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial
CONCLUSION: In the MIYABI ND-C study, molidustat appeared to be an efficacious and generally well-tolerated alternative to darbepoetin for the treatment of renal anemia in Japanese patients who were not undergoing dialysis and were not receiving ESA treatment.PMID:34569489 | DOI:10.1159/000518071 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
CONCLUSION: Molidustat was noninferior to darbepoetin and maintained Hb levels in the prespecified target range in patients with renal anemia not undergoing dialysis and previously treated with ESA. Molidustat was well tolerated, and no new safety signal was observed.PMID:34569482 | DOI:10.1159/000518072 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial
CONCLUSION: In the MIYABI ND-C study, molidustat appeared to be an efficacious and generally well-tolerated alternative to darbepoetin for the treatment of renal anemia in Japanese patients who were not undergoing dialysis and were not receiving ESA treatment.PMID:34569489 | DOI:10.1159/000518071 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial
CONCLUSION: In the MIYABI ND-C study, molidustat appeared to be an efficacious and generally well-tolerated alternative to darbepoetin for the treatment of renal anemia in Japanese patients who were not undergoing dialysis and were not receiving ESA treatment.PMID:34569489 | DOI:10.1159/000518071 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
CONCLUSION: Molidustat was noninferior to darbepoetin and maintained Hb levels in the prespecified target range in patients with renal anemia not undergoing dialysis and previously treated with ESA. Molidustat was well tolerated, and no new safety signal was observed.PMID:34569482 | DOI:10.1159/000518072 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
CONCLUSION: Molidustat was noninferior to darbepoetin and maintained Hb levels in the prespecified target range in patients with renal anemia not undergoing dialysis and previously treated with ESA. Molidustat was well tolerated, and no new safety signal was observed.PMID:34569482 | DOI:10.1159/000518072 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 27, 2021 Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
